PolyPid Ltd.
PYPDHealthcare|Biotechnology|IL
$6.14
+0.47 (+8.29%)
DCF Value
$0.12
Tangible Book / Share
$0.24
Cash / Share
$0.29
Financials
Financial Snapshot
Market Cap
$124.7M
Enterprise Value
$119.7M
Revenue (TTM)
$0.00
Net Income (TTM)
-$31.5M
Cash & Investments
$6.6M
Net Cash
$5.0M
Free Cash Flow (TTM)
$0.00
Operating CF (TTM)
$0.00
Debt/Equity
0.29
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $17.8M | $17.9M | $7.3M | $26.6M | $44.5M | $32.2M | $12.6M | $5.6M | $15.6M | $12.9M | $6.6M | |
| Operating Cash Flow | -$9.7M | -$12.3M | -$16.7M | -$17.4M | -$21.6M | -$32.4M | -$34.3M | -$17.2M | -$22.0M | $0.00 | $0.00 | |
| Free Cash Flow | -$10.3M | -$14.2M | -$19.8M | -$18.2M | -$22.8M | -$35.4M | -$36.1M | -$17.4M | -$22.0M | $0.00 | $0.00 | |
| Capital Expenditure | -$539.0K | -$1.9M | -$3.1M | -$879.0K | -$1.2M | -$3.0M | -$1.8M | -$196.0K | -$76.0K | $0.00 | $0.00 | |
| Financing Cash Flow | $26.3M | $14.4M | $9.4M | $37.7M | $62.8M | $1.0M | $16.4M | $10.0M | $32.4M | $0.00 | $0.00 |
R&D Spending
R&D (TTM)
$23.4M
R&D Intensity
—
R&D Growth vs Prior
-1.9%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $7.7M | $9.7M | $12.6M | $14.1M | $17.0M | $30.4M | $28.0M | $16.1M | $22.8M | $23.8M | $23.4M | |
| SG&A | $2.6M | $4.1M | $5.8M | $3.5M | $9.3M | $12.5M | $10.9M | $6.7M | $5.2M | $9.2M | $8.2M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $127.0K | $205.0K | $411.0K | $947.0K | $1.0M | $1.1M | $1.7M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | -$127.0K | -$205.0K | -$411.0K | -$947.0K | -$1.0M | -$1.1M | -$1.7M | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $7.7M | $9.7M | $12.6M | $14.1M | $17.0M | $30.4M | $28.0M | $16.1M | $22.8M | $23.8M | $23.4M | |
| SG&A | $2.6M | $4.1M | $5.8M | $3.5M | $9.3M | $12.5M | $10.9M | $6.7M | $5.2M | $9.2M | $8.2M | |
| Operating Income | -$10.3M | -$13.8M | -$18.4M | -$18.6M | -$26.3M | -$43.1M | -$38.9M | -$22.9M | -$28.0M | -$33.0M | $1.2M | |
| Interest Expense | $108.0K | $16.0K | $42.0K | $15.0K | $17.0K | $0.00 | $1.3M | $1.7M | $1.5M | $685.0K | $24.0K | |
| Pretax Income | -$11.4M | -$54.5M | $5.9M | -$6.9M | -$36.9M | -$42.6M | -$39.4M | -$23.8M | -$29.0M | -$34.2M | -$31.6M | |
| Net Income | -$11.4M | -$54.5M | $5.9M | -$6.9M | -$35.3M | -$40.7M | -$39.5M | -$23.9M | -$29.0M | -$34.2M | -$31.5M | |
| EPS (Diluted) | -77.48 | -370.58 | 26.70 | -15.03 | -122.10 | -67.80 | -61.20 | -16.99 | -4.91 | -2.09 | -1.48 | |
| EBITDA | -$10.1M | -$13.6M | -$42.1M | -$5.9M | -$35.9M | -$41.5M | -$36.4M | -$20.3M | -$25.8M | -$32.0M | -$29.7M | |
| Shares Out. (M) | 0.59 | 0.59 | 0.89 | 0.89 | 1.28 | 1.25 | 1.30 | 1.40 | 5.91 | 16.35 | 22.64 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.2M | $3.9M | $7.3M | $3.9M | $4.3M | $9.8M | $8.6M | $5.6M | $15.6M | $6.4M | $6.6M | |
| Short-Term Investments | $7.5M | $14.0M | $0.00 | $22.7M | $40.2M | $22.4M | $4.0M | $0.00 | $0.00 | $6.5M | $0.00 | |
| Total Current Assets | $18.3M | $18.7M | $8.0M | $27.4M | $47.2M | $34.8M | $14.2M | $6.1M | $16.6M | $15.2M | $8.9M | |
| Total Assets | $19.2M | $23.0M | $14.5M | $33.8M | $75.8M | $44.2M | $26.0M | $15.4M | $25.2M | $22.3M | $15.2M | |
| Total Current Liabilities | $1.7M | $3.4M | $3.7M | $2.6M | $2.9M | $8.1M | $8.6M | $7.3M | $12.7M | $7.7M | $6.6M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $7.6M | $6.4M | $634.0K | $0.00 | $0.00 | |
| Total Liabilities | $53.2M | $111.6M | $96.2M | $2.8M | $3.1M | $8.3M | $20.1M | $17.5M | $17.5M | $11.3M | $9.8M | |
| Stockholders' Equity | -$34.0M | -$88.6M | -$81.7M | $30.9M | $72.8M | $36.0M | $5.8M | -$2.1M | $7.7M | $11.0M | $5.4M | |
| Retained Earnings | -$36.6M | -$92.3M | -$86.4M | -$93.3M | -$132.3M | -$174.9M | -$214.4M | -$238.3M | -$267.3M | -$301.5M | -$317.1M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.7M | -$12.3M | -$16.7M | -$17.4M | -$21.6M | -$32.4M | -$34.3M | -$17.2M | -$22.0M | $0.00 | $0.00 | |
| Capital Expenditure | -$539.0K | -$1.9M | -$3.1M | -$879.0K | -$1.2M | -$3.0M | -$1.8M | -$196.0K | -$76.0K | $0.00 | $0.00 | |
| Free Cash Flow | -$10.3M | -$14.2M | -$19.8M | -$18.2M | -$22.8M | -$35.4M | -$36.1M | -$17.4M | -$22.0M | $0.00 | $0.00 | |
| Investing Cash Flow | -$8.1M | -$8.4M | $11.0M | -$23.6M | -$40.8M | $36.9M | $16.6M | $3.8M | -$330.0K | $0.00 | $0.00 | |
| Financing Cash Flow | $26.3M | $14.4M | $9.4M | $37.7M | $62.8M | $1.0M | $16.4M | $10.0M | $32.4M | $0.00 | $0.00 | |
| Issuance of Stock | $26.3M | $14.4M | $9.4M | $37.7M | $62.8M | $1.0M | $5.1M | $12.7M | $35.9M | $0.00 | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $11.3M | -$2.6M | -$3.3M | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Change in Cash | $8.5M | -$6.3M | $3.6M | -$3.2M | $410.0K | $5.5M | -$1.2M | -$3.5M | $10.2M | -$9.2M | -$8.5M |
Dilution Tracker
Shares outstanding grew 1179.8% over 5 years — significant dilution
Shares Outstanding
20M
5-Year Share Growth
+1179.8%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.59 | 0.59 | 0.89 | 0.89 | 1.28 | 1.25 | 1.30 | 1.40 | 5.91 | 16.35 | 22.64 | |
| Change vs Prior % | — | 0.0% | 50.7% | 0.0% | 44.1% | -2.3% | 3.8% | 8.4% | 321.0% | 176.5% | 38.4% | |
| Stock Issuance | $26.3M | $14.4M | $9.4M | $37.7M | $62.8M | $1.0M | $5.1M | $12.7M | $35.9M | $0.00 | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 33.5% | 61.5% | -7.2% | -22.3% | -48.5% | -113.2% | -678.1% | 1138.6% | -377.7% | -311.4% | -311.1% | |
| ROA % | -59.2% | -237.1% | 40.9% | -20.5% | -46.6% | -92.0% | -152.2% | -155.2% | -115.1% | -153.2% | -206.8% | |
| ROIC % | -58.5% | -70.3% | -170.1% | -59.5% | -36.0% | -119.3% | -173.6% | -181.1% | -138.4% | -197.2% | 11.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | -17.6% | -61.4% | -100.5% | -130.4% | -6.9% | -10.5% | -53.9% | 100.0% | 0.0% | 0.0% | |
| Operating Income | 9.0% | -34.5% | -33.1% | -1.1% | -41.6% | -64.2% | 9.9% | 41.2% | -22.6% | -17.6% | |
| Net Income | -38.6% | -378.3% | 110.9% | -216.7% | -411.6% | -15.3% | 2.9% | 39.6% | -21.6% | -17.7% | |
| EPS (Diluted) | -106.0% | -378.3% | 107.2% | -156.3% | -712.4% | 44.5% | 9.7% | 72.2% | 71.1% | 57.4% | |
| Operating Cash Flow | -48.1% | -26.5% | -35.5% | -4.1% | -24.4% | -50.0% | -6.0% | 49.8% | -27.4% | 100.0% | |
| Free Cash Flow | -53.6% | -38.2% | -39.1% | 7.7% | -24.9% | -55.4% | -2.0% | 51.7% | -26.4% | 100.0% | |
| R&D Expense | 36.8% | 26.3% | 28.9% | 12.2% | 20.4% | 79.4% | -8.0% | -42.3% | 41.3% | 4.4% | |
| SG&A Expense | -13.0% | 59.3% | 43.1% | -39.3% | 164.0% | 33.6% | -12.5% | -38.3% | -22.3% | 75.5% | |
| Total Assets | 675.7% | 19.5% | -37.0% | 133.1% | 124.6% | -41.7% | -41.3% | -40.8% | 64.1% | -11.6% | |
| Book Value / Share | -21749.5% | -161.0% | 38.8% | 137.9% | 63.2% | -49.4% | -84.4% | -133.2% | 187.1% | -48.3% | |
| Debt | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -14.2% | -18.4% | -70.9% | |
| Diluted Shares | -32.7% | 0.0% | 50.7% | 0.0% | 44.1% | -2.3% | 3.8% | 8.4% | 321.0% | 176.5% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B25.80
10Y Low / Med / High2.34 / 5.98 / 16.33
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.12
Tangible Book / Share
$0.24
Cash / Share
$0.29
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -7.36 | -1.54 | 21.35 | -37.92 | -66.29 | -2.54 | -0.34 | -0.22 | -0.62 | -2.08 | -4.15 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -9.87 | -3.78 | -6.18 | 16.33 | 5.21 | 5.98 | 4.65 | -2.55 | 2.34 | 6.47 | 25.80 | |
| EV/EBITDA | -32.08 | -24.37 | -11.81 | -84.36 | -10.46 | -4.94 | -0.89 | -0.57 | -0.46 | -2.10 | -4.03 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-28.19
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $35.1M | $9.7M | $24.7M |
| Net Income | $2.2M | -$26.8M | -$6.8M |
| EPS | $0.10 | $-1.05 | $-0.41 |
| # Analysts (EPS) | 4 | 4 | 2 |